Monitor Fortrea's next quarterly earnings for any revenue contribution or margin impact from the acquired assets, and for updates on client wins leveraging the expanded early-phase platform.
Price Chart
Executive Summary
Fortrea completed the acquisition of Worldwide Clinical Trials' Early Phase Services division for ~$45M in cash, adding a 200-bed CRU in San Antonio, a bioanalytical lab in Austin, and a biospecimen facility in Pflugerville. The deal expands Fortrea's early-phase bed capacity to >570 beds globally and adds in-house large/small molecule bioanalytical capabilities, strengthening its end-to-end CRO platform. The acquisition is modest in size (~$45M) and strategically bolt-on, with no financial terms or synergy targets disclosed.
Key Financial Metrics
Key Facts
- All-cash acquisition valued at approximately $45 million.
- Adds a 200-bed GCP-compliant CRU in San Antonio, Texas; a 60,000 sq ft GLP-compliant bioanalytical lab in Austin, Texas; and a biospecimen storage facility in Pflugerville, Texas.
- Expands Fortrea's early-phase clinical capacity to more than 570 beds globally.
- Adds dedicated large and small molecule bioanalytical capabilities in-house.
- Strategic alliance agreement with Worldwide Clinical Trials to ensure continuity during transition.
- Barclays served as financial advisor; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. as legal counsel.
Financial Impact
~$45 million all-cash acquisition; no revenue, earnings, or synergy targets disclosed.
Risk Factors
- Integration risks — combining operations, systems, and personnel across three new sites.
- No disclosed financial targets — unclear near-term accretion or dilution to earnings.
- Modest deal size (~$45M) relative to Fortrea's scale — unlikely to materially shift financial trajectory alone.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3383875 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | Press Release | $23.92 | awaiting T+1 | — | $23.82 (−0.44%) |
Oct 19, 2026 6d ago | Press Release | $22.78 $24.06 | ▲ +5.62% | ▲ +5.09% | $23.82 (+4.54%) |
Oct 5, 2026 21d ago | Press Release | $21.11 $20.78 | ▼ −1.56% | ▼ −2.11% | $23.82 (+12.81%) |
Sep 30, 2026 25d ago | 8-K | $19.40 $20.00 | ▲ +3.09% | ▲ +2.35% | $23.82 (+22.76%) |
Sep 10, 2026 6w ago | Press Release | $17.20 $17.41 | ▲ +1.22% | ▲ +1.67% | $23.82 (+38.46%) |
Sep 10, 2026 6w ago | 8-K | $17.02 $17.20 | ▲ +1.06% | ▲ +0.21% | $23.82 (+39.92%) |
Sep 2, 2026 7w ago | Press Release | $18.36 $18.62 | ▲ +1.42% | ▲ +0.37% | $23.82 (+29.71%) |
Aug 22, 2026 9w ago | Institutional Cluster | $18.31 $18.27 | ▼ −0.22% | ▼ −0.54% | $23.82 (+30.07%) |
Aug 7, 2026 11w ago | Insider Cluster | $18.99 $19.52 | ▲ +2.79% | ▲ +3.11% | $23.82 (+25.41%) |
Aug 6, 2026 11w ago | Insider Cluster | $18.43 $18.99 | ▲ +3.04% | ▲ +3.07% | $23.82 (+29.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers